U.S. Government Accountability Office, 2003-06-04: GAO report finding that NIH held no patent on paclitaxel itself because the compound was already public, that Bristol-Myers licensed three NIH method patents (5,496,804; 5,496,846; 6,150,398) at a 0.5 percent royalty, and that NIH received about $35 million through 2002 while worldwide Taxol sales exceeded $9 billion.
NIH stated that it could not patent paclitaxel because the relevant information about the compound was already in the public domain.
p. 19 (incl. n. 27)
U.S. Government Accountability Office, 2003-06-04: GAO report finding that NIH held no patent on paclitaxel itself because the compound was already public, that Bristol-Myers licensed three NIH method patents (5,496,804; 5,496,846; 6,150,398) at a 0.5 percent royalty, and that NIH received about $35 million through 2002 while worldwide Taxol sales exceeded $9 billion. Funder/conflicts: n/a (legislative-branch audit; BMS and NIH both commented and their comments are in the report). Maker: Bristol-Myers Squibb. Comparator: n/a. Directly contradicts the book's claim that BMS 'patented a synthetic version': the patents BMS held were NIH method-of-use patents licensed in 1996, and NIH could not patent the molecule. Medicare paid $687 million for Taxol 1994-1999 (p. 18). Also filed as CHE-16 (claims C6, F1). Study type: other.
